Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass

La, Cole; Nam, JH; Chambers, JT; Schwartz, P.E.

doi:10.1016/0020-7292(91)90580-x

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…UGP is a promising new tumor marker for gynecological disease (7,8,(20)(21)(22)(23). However, before its measurement can be introduced in clinical practice, it is necessary to clarify the type of sample (e.g., 24 hr, morning samples), the expression of results (e.g., units per liter, units per creatinine excretion), and, finally, the cutoff to be adopted.…”

Section: Discussionmentioning

confidence: 99%

Urinary gonadotropin peptide: Collection of specimens and cutoff levels

Plebani

Navaglia

Bacelle

et al. 1995

Clinical Laboratory Analysis

View full text Add to dashboard Cite

A low-molecular-weight form of human chorionic gonadotropin (hCG), urinary gonadotropin peptide (UGP), has been isolated from the urine of pregnant women and of patients with cancer, mainly of gynecological origin. The clinical value of UGP measurement in gynecological diseases is under investigation but a preliminary study is necessary in order to ascertain whether there is a circadian rhythm in UGP production, to clarify the best way to express the results, and to establish the cutoff and decisional values. In our work we demonstrated a significant correlation between the UGP output and the UGP excretion normalized for urinary creatinine. A very significant agreement was even found in 24-hr urine collections and UGP concentration of a single morning specimen from the same patients. No evident circadian rhythm was found, although some patients presented morning levels of UGP higher than in other collections. UGP postmenopausal levels were higher than premenopausal. The cutoff level, adopting the 95.0 percentile, was 200 pmol/mol creatinine.

show abstract

Section: Discussionmentioning

confidence: 99%

Urinary gonadotropin peptide: Collection of specimens and cutoff levels

Plebani

Navaglia

Bacelle

et al. 1995

Clinical Laboratory Analysis

View full text Add to dashboard Cite

show abstract

“…The value of the UGF assay as a supplement to CA 125 in differentiating between benign and malignant pelvic masses has been evaluated in two studies. One study (17) showed that, with specific cutoff values (±8 fmol/ml for UGF and ±200 U/ ml for CA 125), a sensitivity of 86% could be achieved with minimal false detection of benign disease (∞1.2%). Another study, however, disputed the significance of this finding, as the urinary ßcore fragment in conjunction with CA 125 did not aid the differentation of malignant from benign masses (18).…”

Section: Urinary Gonadotropin Fragmentsmentioning

confidence: 99%

New endocrine tumor markers of gynecologic malignancies, A review

Kauppila

Santala

1999

Acta Obstet Gynecol Scand

View full text Add to dashboard Cite

Urinary gonadotropin fragment, a new tumor marker. II. Differentiating a benign from a malignant pelvic mass

Cited by 2 publications

References 0 publications

Urinary gonadotropin peptide: Collection of specimens and cutoff levels

Urinary gonadotropin peptide: Collection of specimens and cutoff levels

New endocrine tumor markers of gynecologic malignancies, A review

Contact Info

Product

Resources

About